Showing papers in "Journal of Thoracic Oncology in 2016"
Imperial College London1, University of Barcelona2, Keio University3, University of Duisburg-Essen4, Queen's University5, Peter MacCallum Cancer Centre6, University of Michigan7, University of São Paulo8, Yale University9, Northern General Hospital10, University of Caen Lower Normandy11, Fred Hutchinson Cancer Research Center12, University of Oxford13, Memorial Sloan Kettering Cancer Center14, University of Sydney15, Sungkyunkwan University16, Seoul National University17, Kyorin University18, University of Copenhagen19, Nippon Medical School20, Katholieke Universiteit Leuven21, University of Texas MD Anderson Cancer Center22, University of Antwerp23, Hyogo College of Medicine24, University of Western Australia25, Glenfield Hospital26, Cleveland Clinic27, Icahn School of Medicine at Mount Sinai28, University of Turin29, Université libre de Bruxelles30, Juntendo University31, National Cancer Research Institute32, Mayo Clinic33, University of Toronto34, Sinai Grace Hospital35, Netherlands Cancer Institute36, Hiroshima University37, City of Hope National Medical Center38, University of Chicago39, New York University40, Georgetown University41, University of Tokushima42, University of Pisa43, Osaka University44, University of Valencia45, Good Samaritan Hospital46, Military Medical Academy47, Fundación Favaloro48, Autonomous University of Barcelona49, Complutense University of Madrid50, University of Oviedo51, National and Kapodistrian University of Athens52, Rovira i Virgili University53, Autonomous University of Madrid54, Ghent University55
TL;DR: The methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition of the TNM Classification for lung cancer due to be published late 2016 are described.
2,826 citations
TL;DR: Lung cancer will continue to be a major health problem well through the first half of this century and preventive strategies, particularly tobacco control, tailored to populations at highest risk are key to reducing the global burden of lung cancer.
449 citations
Memorial Sloan Kettering Cancer Center1, Keio University2, Beth Israel Deaconess Medical Center3, Mount Sinai Hospital4, Yale University5, Fox Chase Cancer Center6, New Generation University College7, University of Chicago8, New York University9, Imperial College London10, Radboud University Nijmegen11, University of Barcelona12, Peter MacCallum Cancer Centre13, University of Michigan14, University of São Paulo15, Fred Hutchinson Cancer Research Center16, University of Duisburg-Essen17, Northern General Hospital18, University of Caen Lower Normandy19, Churchill Hospital20, Queen's University21, University of Sydney22, Sungkyunkwan University23, Seoul National University24, Kyorin University25, University of Copenhagen26, Nippon Medical School27, Katholieke Universiteit Leuven28, British Hospital29, University of Texas MD Anderson Cancer Center30, University of Antwerp31, Hyogo College of Medicine32, University of Western Australia33, Glenfield Hospital34, Cleveland Clinic35, Icahn School of Medicine at Mount Sinai36, University of Turin37, Université libre de Bruxelles38, Juntendo University39, National Cancer Research Institute40, Mayo Clinic41, Princess Margaret Cancer Centre42, Sinai Grace Hospital43, Netherlands Cancer Institute44, Hiroshima University45, City of Hope National Medical Center46, Georgetown University47, University of Tokushima48, University of Pisa49, Osaka University50
TL;DR: Codes for the primary tumor categories of AIS and minimally invasive adenocarcinoma (MIA) and a uniform way to measure tumor size in part‐solid tumors for the eighth edition of the tumor, node, and metastasis classification of lung cancer are proposed.
431 citations
TL;DR: This review focuses on the immune contexture; the tumor‐suppressing roles of tumor‐infiltrating lymphocytes; and the relevance of thisimmune contexture for cancer diagnostics, prognostication, and treatment allocation, with an emphasis on non–small cell lung cancer.
344 citations
University of Duisburg-Essen1, Guangdong General Hospital2, Peking Union Medical College3, McGill University Health Centre4, Queensland University of Technology5, Wakayama Medical University6, The Chinese University of Hong Kong7, The Royal Marsden NHS Foundation Trust8, Harvard University9, Boehringer Ingelheim10, National Taiwan University11
TL;DR: In this article, a randomized, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harboring an EGFR activating mutation was conducted.
278 citations
TL;DR: The challenges remaining to harmonize PD‐L1 detection and interpretation for best patient care are described and described.
270 citations
TL;DR: The prognostic value of clinical and pathological TNM staging in patients with SCLC is confirmed, and continued usage for SclC is recommended in relation to proposed changes to T, N, and M descriptors for NSCLC in the eighth edition.
269 citations
TL;DR: Diverse targetable METex14 alterations were identified in patients with NSCLC across age groups, including elderly patients, and in all majorNSCLC histologic subtypes with an overall frequency of 2.7%.
263 citations
TL;DR: The data suggest that the rate of 5‐year survival among patients with EGFR‐mutant metastatic lung adenocarcinoma treated with erlotinib or gefitinib is 14.6%, and clinicians can gain an enhanced estimation of long‐term outcomes in this population.
245 citations
TL;DR: DNA derived from NSCLC tumors can be detected with high sensitivity in urine and plasma, enabling diagnostic detection and monitoring of therapeutic response from these noninvasive “liquid biopsy” samples.
240 citations
TL;DR: Several promising observations in mesothelioma pathology and genetics have been made in the past decade and are now the subject of further investigation to determine if they can be validated in ways that will significantly impact clinical practice.
University of Texas MD Anderson Cancer Center1, University of Turin2, University of Colorado Denver3, Ohio State University4, Medical University of South Carolina5, Fudan University6, Erasmus University Rotterdam7, Fiona Stanley Hospital8, Princess Margaret Cancer Centre9, Memorial Sloan Kettering Cancer Center10, University of Barcelona11, Keio University12, University of Antwerp13, University of Toronto14, Emory University15, Icahn School of Medicine at Mount Sinai16, University of Lausanne17, University of California, Irvine18, Mahidol University19, Harvard University20, The Chinese University of Hong Kong21, Stanford University22, Medical University of Vienna23, Paul Sabatier University24, Johns Hopkins University25, Yale University26, Yale Cancer Center27, Fred Hutchinson Cancer Research Center28, University of California, Davis29, New York University30
TL;DR: The International Association for the Study of Lung Cancer has gathered experts in different areas of lung cancer research and management to summarize the most significant scientific advancements related to prevention and therapy of Lung cancer during the past year.
TL;DR: The radiomics of lung cancer screening computed tomography scans at baseline can be used to assess risk for development of cancer.
TL;DR: Exosome protein profiling is demonstrated to be a promising diagnostic tool in lung cancer independently of stage and histological subtype and multi-million dollar multimarker models could make a fair separation of patients.
TL;DR: There is an urgent need for effective predictive biomarkers to identify patients likely to benefit from anti-PD-1/PD-L1 antibodies in NSCLC and the existing data on predictive markers for the efficacy are reviewed.
TL;DR: Clinical and pathologic criteria are presented to identify two foci as separate primary lung cancers versus a metastasis and few features are definitive; many commonly used characteristics are suggestive but associated with a substantial rate of misclassification.
TL;DR: An extensive analysis has produced stage classification proposals for lung cancer with a robust degree of discriminatory consistency and general applicability and external validation is encouraged to identify areas of strength and weakness.
TL;DR: IL‐6 may contribute to maintenance of a paracrine loop that functions as part of the communication between CAFs and NSCLC cells, resulting in chemoresistance.
TL;DR: Her2 mutations are not associated with HER2 amplification, thus suggesting a distinct entity and therapeutic target, and patient cohorts for the study of HER2‐targeted agents should be defined by the specific HER2 alteration present.
TL;DR: Leptomeningeal metastases were much more frequent in patients with NSCLC harboring EGFR mutations, and EGFR TKIs were the optimal treatment for LM, and active treatment with WBRT did not prolong OS for EGFR‐mutated patients.
TL;DR: The importance of the new genetic finding in cardiac myxomas, namely somatic mutations in the PRKAR1A gene underscores the importance of this alteration in the pathogenesis of these tumors.
Genome Institute of Singapore1, University of California, San Francisco2, Princess Margaret Cancer Centre3, New York University4, University of California, Davis5, Tel Aviv University6, Greater Baltimore Medical Center7, University of Texas MD Anderson Cancer Center8, Thomas Jefferson University9, Kindai University10, University of Zurich11, Icahn School of Medicine at Mount Sinai12, Yale Cancer Center13, Ohio State University14, University of Colorado Boulder15, The Chinese University of Hong Kong16
TL;DR: Key pathologic, diagnostic, and therapeutic considerations, such as optimal choice of EGFR TKI and management of brain metastasis, are discussed and recommendations are made for clinical guidelines and research priorities.
TL;DR: The findings have established that relative to the huge health, social, and economic burden associated with lung cancer, the level of world research output lags significantly behind that of research on other malignancies.
TL;DR: This study revealed the frequencies and periods of development from PGGNs and HGGNs into part‐solid nodules and Invasive adenocarcinomas were diagnosed only among the part‐ Solid nodules.
TL;DR: The PD‐L1/programmed cell death 1 pathway may contribute to the progression of smoking‐associated tumors in lung adenocarcinoma.
TL;DR: This work proposes to tailor TNM classification of multiple pulmonary sites of lung cancer to reflect the unique aspects of four different patterns of presentation, which will lead to more consistent classification and clarity in communication and facilitate further research in the nature and optimal treatment of these entities.
University of Colorado Denver1, University of Texas Southwestern Medical Center2, Stanford University3, Netherlands Cancer Institute4, Joseph Fourier University5, Memorial Sloan Kettering Cancer Center6, Vanderbilt University7, Harvard University8, University of Cologne9, National Cancer Research Institute10, Washington University in St. Louis11, University of Texas MD Anderson Cancer Center12, Fred Hutchinson Cancer Research Center13, Johns Hopkins University14, Cancer Research UK15, National Institutes of Health16, Cleveland Clinic17, San Antonio River Authority18, Mayo Clinic19, Tongji University20, Case Western Reserve University21, Sungkyunkwan University22, Indiana University – Purdue University Indianapolis23, University of Maryland, Baltimore24, Georgetown University25, University of Chicago26, Emory University27, University of California, Davis28, VU University Amsterdam29, University of Manchester30, University of Ottawa31
TL;DR: This book aims to provide a history of web exceptionalism from 1989 to 2002, a period chosen in order to explore its roots as well as specific cases up to and including the year in which descriptions of “Web 2.0” began to circulate.
TL;DR: Unfit patients with ultracentral tumors who were treated using this scheme had a high local control and a median survival of 15.9 months, despite manifestation of rates of a fatal lung bleeding comparable to those seen with conventional radiotherapy for endobronchial tumors, the overall rate of G5 toxicity is of potential concern.
TL;DR: Real‐world data suggest that ctDNA is a feasible sample for EGFR mutation analysis, and it is important to conduct mutation testing of both tumor and plasma samples in specialized laboratories, using robust/sensitive methods to ensure that patients receive appropriate treatments that target the molecular features of their disease.